Resource impact statement
No significant resource impact is anticipated
NICE has recommended cabozantinib as an option for treating advanced hepatocellular carcinoma in adults who have had sorafenib, only if:
- they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group performance status of 0 or 1 and
- the company provides it according to the commercial arrangement.
This recommendation is not intended to affect treatment with cabozantinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).
This is because the technology is a further treatment option and the population size is small.
Cabozantinib has a discount that is commercial in confidence. For enquiries about the patient access scheme contact medical.information.uk@ipsen.com.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
ISBN: 978-1-4731-4842-0
This page was last updated: